Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis
Therapeutic Advances in Respiratory Disease · 2025-01 · 19
DOI: 10.1177/17534666241309795 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 02.01.2025. Verfasst von Rebecca Keith und 1 weiteren Autor:innen. Beteiligte Einrichtung: National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Cyclic Nucleotide Phosphodiesterases, Type 4, Idiopathic Pulmonary Fibrosis, Disease Progression. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The authors did not receive payment for development of this article. The page processing charge for this article would be paid by Boehringer Ingelheim..
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is often regarded as the archetypal progressive fibrosing interstitial lung disease (ILD). The term “progressive pulmonary fibrosis” (PPF) generally describes progressive lung fibrosis in an individual with an ILD other than IPF. Both IPF and PPF are associated with loss of lung function, worsening dyspnea and quality of life, and premature death. Current treatments slow the decline in lung function but have side effects that may deter the initiation or continuation of treatment. There remains a high unmet need for additional therapies that can be used alone or in combination with current therapies to preserve lung function in patients with IPF and PPF. Phosphodiesterase-4 (PDE4) is an enzyme involved in the regulation of inflammatory processes. Pre-clinical studies have shown that preferential inhibition of PDE4B has anti-inflammatory and antifibrotic effects and a lower potential for gastrointestinal adverse events than pan-PDE4 inhibition. The preferential PDE4B inhibitor nerandomilast demonstrated efficacy in preserving lung function in a phase II trial in patients with IPF and is under investigation in phase III trials as a treatment for IPF and PPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA.
- University of Texas Health San Antonio and the South Texas Veterans Health Care System, San Antonio, TX, USA.
ORCID-Profile: Rebecca Keith, Anoop M Nambiar
Förderung
- The authors did not receive payment for development of this article. The page processing charge for this article would be paid by Boehringer Ingelheim.
Zitieren
APA
Keith, R., & Nambiar, A. M. (2025). Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 19. https://doi.org/10.1177/17534666241309795
Vancouver
Keith R, Nambiar AM. Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis. Therapeutic Advances in Respiratory Disease. 2025;19. doi:10.1177/17534666241309795
BibTeX
@article{Keith2025,
author = {Keith, Rebecca and Nambiar, Anoop M},
title = {Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2025},
volume = {19},
doi = {10.1177/17534666241309795}
}
EUVIMED